TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint May 31, 2013
TCL Archive In Brief: Oldham to Leave NCI, Herberman Acting Head Of BRMP; Lansky Appointed Director Of ICC November 11, 1983